Probiotics for Inflammatory Bowel Disease; A Deep Dive into their Impact on Disease Course and Associated Health Risks


Цитировать

Полный текст

Аннотация

:To date, the underlying pathology of inflammatory bowel disease (IBD) is undetermined. Disturbance of intestinal gut microbiota was implicated in many health diseases, including IBD. Increasing evidence suggests that probiotics play a beneficial role in restoring the balance of the gut ecosystem. This review searched multiple databases for relevant works that examined probiotics' possible benefits in adults with IBD. Probiotic mode of action in ulcerative colitis patients and Crohn's disease were examined with respect to probiotic strain, their benefits, and their advantages in adult cases. Eligible studies for inclusion were assessed and analyzed. They were effective in reducing IBD disease course, inducing and maintaining remission, particularly for ulcerative colitis patients, with good efficacy and safety profile. However, the evidence for Crohn's disease was lacking. Probiotics positively affect IBD-related risks, reducing the risk of gastrointestinal malignancy and optimizing treating them. Additionally, they improved reduced fertility odds for both genders. The osteoporosis risk among IBD patients was also reduced, although the duration of use and dose were still not established. There was an encouraging role for them in reducing IBD -cardiovascular risks among cases with acute myocardial infarction and those with chronic heart failure. Finally, they had novel use in reducing IBD-related depression and improved overall mental health. In conclusion, we recommend probiotics as an adjuvant therapeutic option for IBD therapy for ulcerative colitis; however, their role in Crohn's disease needs further research.

Об авторах

Wassan Hassan

Department of Obstetrics and Gynecology, Mustansiriyah University

Автор, ответственный за переписку.
Email: info@benthamscience.net

Methaq Al-kaabi

Department of Pathology, Mustansiriyah University

Email: info@benthamscience.net

Nabeeha Akram

Department of Pediatrics, Mustansiriyah University

Email: info@benthamscience.net

Mustafa Kassim

Department of Medicine, Ovidius University

Email: info@benthamscience.net

Alexandru Pantazi

Department of Pediatrics, Ovidius University

Email: info@benthamscience.net

Список литературы

  1. Agrawal, M.; Allin, K.H.; Petralia, F.; Colombel, J.F.; Jess, T. Multiomics to elucidate inflammatory bowel disease risk factors and pathways. Nat. Rev. Gastroenterol. Hepatol., 2022, 19(6), 399-409. doi: 10.1038/s41575-022-00593-y PMID: 35301463
  2. Liu, X.Y.; Tang, H.; Zhou, Q.Y.; Zeng, Y.L.; Chen, D.; Xu, H.; Li, Y.; Tan, B.; Qian, J.M. Advancing the precision management of inflammatory bowel disease in the era of omics approaches and new technology. World J. Gastroenterol., 2023, 29(2), 272-285. doi: 10.3748/wjg.v29.i2.272 PMID: 36687128
  3. Stange, E.F. Current and future aspects of IBD research and treatment: The 2022 perspective. Frontline Gastroenterol., 2022, 1, 914371. doi: 10.3389/fgstr.2022.914371
  4. Saez, A.; Herrero-Fernandez, B.; Gomez-Bris, R.; Sánchez-Martinez, H.; Gonzalez-Granado, J.M. Pathophysiology of inflammatory bowel disease: Innate immune system. Int. J. Mol. Sci., 2023, 24(2), 1526. doi: 10.3390/ijms24021526 PMID: 36675038
  5. Spiegel, B. Gravity and the gut: A hypothesis of irritable bowel syndrome. Am. J. Gastroenterol., 2022, 117(12), 1933-1947. doi: 10.14309/ajg.0000000000002066 PMID: 36455220
  6. Chey, W.D.; Kurlander, J.; Eswaran, S. Irritable bowel syndrome: A clinical review. JAMA, 2015, 313(9), 949-958. doi: 10.1001/jama.2015.0954 PMID: 25734736
  7. Falloon, K.A.; Fiocchi, C. Current therapy in inflammatory bowel disease: Why and how we need to change? EMJ innov., 2022, 6(1), 40-49. doi: 10.33590/emjinnov/21-00134
  8. Selvamani, S.; Mehta, V.; Ali El Enshasy, H.; Thevarajoo, S.; El Adawi, H.; Zeini, I.; Pham, K.; Varzakas, T.; Abomoelak, B. Efficacy of probiotics-based interventions as therapy for inflammatory bowel disease: A recent update. Saudi J. Biol. Sci., 2022, 29(5), 3546-3567. doi: 10.1016/j.sjbs.2022.02.044 PMID: 35844369
  9. Mishra, J.; Stubbs, M.; Kuang, L.; Vara, N.; Kumar, P.; Kumar, N. Inflammatory bowel disease therapeutics: A focus on probiotic engineering. Mediators Inflamm., 2022, 2022, 9621668. doi: 10.1155/2022/9621668
  10. Marafini, I.; Monteleone, G. Precision medicine in inflammatory bowel diseases. Front. Pharmacol., 2021, 12, 653924. doi: 10.3389/fphar.2021.653924 PMID: 33927628
  11. Singh, T.P.; Natraj, B.H. Next-generation probiotics: A promising approach towards designing personalized medicine. Crit. Rev. Microbiol., 2021, 47(4), 479-498. doi: 10.1080/1040841X.2021.1902940 PMID: 33822669
  12. Huang, C.; Hao, W.; Wang, X.; Zhou, R.; Lin, Q. Probiotics for the treatment of ulcerative colitis: A review of experimental research from 2018 to 2022. Front. Microbiol., 2023, 14, 1211271. doi: 10.3389/fmicb.2023.1211271 PMID: 37485519
  13. König, J.; Wells, J.; Cani, P.D.; García-Ródenas, C.L.; MacDonald, T.; Mercenier, A.; Whyte, J.; Troost, F.; Brummer, R.J. Human intestinal barrier function in health and disease. Clin. Transl. Gastroenterol., 2016, 7(10), e196. doi: 10.1038/ctg.2016.54 PMID: 27763627
  14. Kałużna, A.; Olczyk, P.; Komosińska-Vassev, K. The role of innate and adaptive immune cells in the pathogenesis and development of the inflammatory response in ulcerative colitis. J. Clin. Med., 2022, 11(2), 400. doi: 10.3390/jcm11020400 PMID: 35054093
  15. Loddo, I.; Romano, C. Inflammatory bowel disease: Genetics, epigenetics, and pathogenesis. Front. Immunol., 2015, 6, 551. doi: 10.3389/fimmu.2015.00551 PMID: 26579126
  16. Magro, F.; Langner, C.; Driessen, A.; Ensari, A.; Geboes, K.; Mantzaris, G.J.; Villanacci, V.; Becheanu, G.; Nunes, P.B.; Cathomas, G.; Fries, W.; Jouret-Mourin, A.; Mescoli, C.; de Petris, G.; Rubio, C.A.; Shepherd, N.A.; Vieth, M.; Eliakim, R. European consensus on the histopathology of inflammatory bowel disease. J. Crohn’s Colitis, 2013, 7(10), 827-851. doi: 10.1016/j.crohns.2013.06.001 PMID: 23870728
  17. Jadad, A.R.; Moore, R.A.; Carroll, D.; Jenkinson, C.; Reynolds, D.J.M.; Gavaghan, D.J.; McQuay, H.J. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control. Clin. Trials, 1996, 17(1), 1-12. doi: 10.1016/0197-2456(95)00134-4 PMID: 8721797
  18. Liberati, A.; Altman, D.G.; Tetzlaff, J.; Mulrow, C.; Gøtzsche, P.C.; Ioannidis, J.P.A.; Clarke, M.; Devereaux, P.J.; Kleijnen, J.; Moher, D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration. PLoS Med., 2009, 6(7), e1000100. doi: 10.1371/journal.pmed.1000100 PMID: 19621070
  19. Fijan, S. Probiotics and their antimicrobial effect. Microorganisms, 2023, 11(2), 528. doi: 10.3390/microorganisms11020528 PMID: 36838493
  20. Adak, A.; Khan, M.R. An insight into gut microbiota and its functionalities. Cell. Mol. Life Sci., 2019, 76(3), 473-493. doi: 10.1007/s00018-018-2943-4 PMID: 30317530
  21. Shankar, J. Food habit associated mycobiota composition and their impact on human health. Front. Nutr., 2021, 8, 773577. doi: 10.3389/fnut.2021.773577 PMID: 34881282
  22. Seibold, F. ASCA: genetic marker, predictor of disease, or marker of a response to an environmental antigen? Gut, 2005, 54(9), 1212-1213. doi: 10.1136/gut.2005.065227 PMID: 16099786
  23. Vermeire, S.; Peeters, M.; Vlietinck, R.; Joossens, S.; Hond, E.D.; Bulteel, V.; Bossuyt, X.; Geypens, B.; Rutgeerts, P. Anti-Saccharomyces cerevisiae antibodies (ASCA), phenotypes of IBD, and intestinal permeability: A study in IBD families. Inflamm. Bowel Dis., 2001, 7(1), 8-15. doi: 10.1097/00054725-200102000-00002 PMID: 11233666
  24. Pantazi, A.C.; Kassim, M.A.K.; Nori, W.; Tuta, L.A.; Mihai, C.M.; Chisnoiu, T.; Balasa, A.L.; Mihai, L.; Lupu, A.; Frecus, C.E.; Lupu, V.V.; Chirila, S.I.; Badescu, A.G.; Hangan, L.T.; Cambrea, S.C. Clinical perspectives of gut microbiota in patients with chronic kidney disease and end-stage kidney disease: Where do we stand? Biomedicines, 2023, 11(9), 2480. doi: 10.3390/biomedicines11092480 PMID: 37760920
  25. Ronan, V.; Yeasin, R.; Claud, E.C. Childhood development and the microbiome-the intestinal microbiota in maintenance of health and development of disease during childhood development. Gastroenterology, 2021, 160(2), 495-506. doi: 10.1053/j.gastro.2020.08.065 PMID: 33307032
  26. Ranjha, M.M.A.N.; Shafique, B.; Batool, M.; Kowalczewski, P.Ł.; Shehzad, Q.; Usman, M.; Manzoor, M.F.; Zahra, S.M.; Yaqub, S.; Aadil, R.M. Nutritional and health potential of probiotics: A review. Appl. Sci., 2021, 11(23), 11204.
  27. Piccioni, A.; Cicchinelli, S.; Valletta, F.; De Luca, G.; Longhitano, Y.; Candelli, M.; Ojetti, V.; Sardeo, F.; Navarra, S.; Covino, M.; Franceschi, F. Gut microbiota and autoimmune diseases: A charming real world together with probiotics. Curr. Med. Chem., 2022, 29(18), 3147-3159. doi: 10.2174/0929867328666210922161913 PMID: 34551690
  28. Nori, W.; Akram, N.N.; Mueen Al-kaabi, M. Probiotics in women and pediatrics health; A narrative review. AMJ, 2023, 19(1), 10-16. doi: 10.33091/amj.2023.138442.1021
  29. Cianci, R.; Franza, L.; Massaro, M.G.; Borriello, R.; Tota, A.; Pallozzi, M.; De Vito, F.; Gambassi, G. The crosstalk between gut microbiota, intestinal immunological niche and visceral adipose tissue as a new model for the pathogenesis of metabolic and inflammatory diseases: The paradigm of type 2 diabetes mellitus. Curr. Med. Chem., 2022, 29(18), 3189-3201. doi: 10.2174/0929867329666220105121124 PMID: 34986766
  30. Palai, S.; Derecho, C.M.P.; Kesh, S.S.; Egbuna, C.; Onyeike, P.C. Pre-biotics, probiotics, synbiotics and its importance in the management of diseases. In: Functional Foods and Nutraceuticals; Springer International Publishing: Cham, 2020; pp. 173-196. doi: 10.1007/978-3-030-42319-3_10
  31. Khan, I.; Ullah, N.; Zha, L.; Bai, Y.; Khan, A.; Zhao, T.; Che, T.; Zhang, C. Alteration of gut microbiota in inflammatory bowel disease (IBD): Cause or consequence? IBD treatment targeting the gut microbiome. Pathogens, 2019, 8(3), 126. doi: 10.3390/pathogens8030126 PMID: 31412603
  32. Santana, P.T.; Rosas, S.L.B.; Ribeiro, B.E.; Marinho, Y.; de Souza, H.S.P. Dysbiosis in inflammatory bowel disease: Pathogenic role and potential therapeutic targets. Int. J. Mol. Sci., 2022, 23(7), 3464. doi: 10.3390/ijms23073464 PMID: 35408838
  33. DeGruttola, A.K.; Low, D.; Mizoguchi, A.; Mizoguchi, E. Current understanding of dysbiosis in disease in human and animal models. Inflamm. Bowel Dis., 2016, 22(5), 1137-1150. doi: 10.1097/MIB.0000000000000750 PMID: 27070911
  34. Zheng, J.; Sun, Q.; Zhang, J.; Ng, S.C. The role of gut microbiome in inflammatory bowel disease diagnosis and prognosis. United European Gastroenterol. J., 2022, 10(10), 1091-1102. doi: 10.1002/ueg2.12338 PMID: 36461896
  35. Di Tommaso, N.; Gasbarrini, A.; Ponziani, F.R. Intestinal barrier in human health and disease. Int. J. Environ. Res. Public Health, 2021, 18(23), 12836. doi: 10.3390/ijerph182312836 PMID: 34886561
  36. Sultan, S.; El-Mowafy, M.; Elgaml, A.; Ahmed, T.A.E.; Hassan, H.; Mottawea, W. Metabolic influences of gut microbiota dysbiosis on inflammatory bowel disease. Front. Physiol., 2021, 12, 715506. doi: 10.3389/fphys.2021.715506 PMID: 34646151
  37. Florio, M.; Crudele, L.; Moschetta, A.; Gadaleta, R.M. Discovering the nutrition-microbiota interplay in inflammatory bowel disease: Are we there yet? In: Gut Microbiome, Microbial Metabolites and Cardiometabolic Risk. Endocrinology; Springer, Cham, 2024; pp. 333-371.
  38. Fiorindi, C.; Russo, E.; Balocchini, L.; Amedei, A.; Giudici, F. Inflammatory bowel disease and customized nutritional intervention focusing on gut microbiome balance. Nutrients, 2022, 14(19), 4117. doi: 10.3390/nu14194117 PMID: 36235770
  39. Zhang, Y.; Si, X.; Yang, L.; Wang, H.; Sun, Y.; Liu, N. Association between intestinal microbiota and inflammatory bowel disease. Animal Model. Exp. Med., 2022, 5(4), 311-322. doi: 10.1002/ame2.12255 PMID: 35808814
  40. Valvano, M.; Capannolo, A.; Cesaro, N.; Stefanelli, G.; Fabiani, S.; Frassino, S.; Monaco, S.; Magistroni, M.; Viscido, A.; Latella, G. Nutrition, nutritional status, micronutrients deficiency, and disease course of inflammatory bowel disease. Nutrients, 2023, 15(17), 3824. doi: 10.3390/nu15173824 PMID: 37686856
  41. Gordon, H.; Burisch, J.; Ellul, P.; Karmiris, K.; Katsanos, K.; Allocca, M.; Bamias, G.; Barreiro-De Acosta, M.; Braithwaite, T.; Greuter, T. ECCO guidelines on extraintestinal manifestations in inflammatory bowel disease. J. Crohn’s Colitis, 2023, 18(1), 1-37. doi: 10.1093/ecco-jcc/jjac187
  42. Markowiak-Kopeć, P.; Śliżewska, K. The effect of probiotics on the production of short-chain fatty acids by human intestinal microbiome. Nutrients, 2020, 12(4), 1107. doi: 10.3390/nu12041107 PMID: 32316181
  43. Tiwari, S.K. Bacteriocin-producing probiotic lactic acid bacteria in controlling dysbiosis of the gut microbiota. Front. Cell. Infect. Microbiol., 2022, 12, p. 851140.
  44. Manoharan, D.; Natesan, S.; Billamboz, M.; Jawhara, S. Role of bacteria-derived exopolysaccharides in inflammatory bowel disease with a special focus on cyanobacterial exopolysaccharides. Appl. Microbiol., 2024, 4(1), 250-274. doi: 10.3390/applmicrobiol4010017
  45. Latif, A.; Shehzad, A.; Niazi, S.; Zahid, A.; Ashraf, W.; Iqbal, M.W.; Rehman, A.; Riaz, T.; Aadil, R.M.; Khan, I.M.; Özogul, F.; Rocha, J.M.; Esatbeyoglu, T.; Korma, S.A. Probiotics: mechanism of action, health benefits and their application in food industries. Front. Microbiol., 2023, 14, 1216674. doi: 10.3389/fmicb.2023.1216674 PMID: 37664108
  46. Liu, Y.; Wang, J.; Wu, C. Modulation of gut microbiota and immune system by probiotics, pre-biotics, and post-biotics. Front. Nutr., 2022, 8, 634897. doi: 10.3389/fnut.2021.634897 PMID: 35047537
  47. Cristofori, F.; Dargenio, V.N.; Dargenio, C.; Miniello, V.L.; Barone, M.; Francavilla, R. Anti-inflammatory and immunomodulatory effects of probiotics in gut inflammation: A door to the body. Front. Immunol., 2021, 12, 578386. doi: 10.3389/fimmu.2021.578386 PMID: 33717063
  48. Mascarenhas, M.T.; de Melo, S.O.; Cunha, A.C.L.A.; Ferreira, I.C. Systematic review: Does the use of probiotics generate benefits for patients treating inflammatory intestinal disease? Rev. Med., 2023, 102(3), 201379. doi: 10.11606/issn.1679-9836.v102i3e-201379
  49. Nakamura, Y.; Suzuki, S.; Murakami, S.; Nishimoto, Y.; Higashi, K.; Watarai, N.; Umetsu, J.; Ishii, C.; Ito, Y.; Mori, Y.; Kohno, M.; Yamada, T.; Fukuda, S. Integrated gut microbiome and metabolome analyses identified fecal biomarkers for bowel movement regulation by Bifidobacterium longum BB536 supplementation: A RCT. Comput. Struct. Biotechnol. J., 2022, 20, 5847-5858. doi: 10.1016/j.csbj.2022.10.026 PMID: 36382178
  50. Bjarnason, I.; Sission, G.; Hayee, B.H. A randomised, double-blind, placebo-controlled trial of a multi-strain probiotic in patients with asymptomatic ulcerative colitis and Crohn’s disease. Inflammopharmacology, 2019, 27(3), 465-473. doi: 10.1007/s10787-019-00595-4 PMID: 31054010
  51. Caviglia, G.P.; De Blasio, F.; Vernero, M.; Armandi, A.; Rosso, C.; Saracco, G.M.; Bugianesi, E.; Astegiano, M.; Ribaldone, D.G. Efficacy of a preparation based on calcium butyrate, Bifidobacterium bifidum, Bifidobacterium lactis, and fructooligosaccharides in the prevention of relapse in ulcerative colitis: A prospective observational study. J. Clin. Med., 2021, 10(21), 4961. doi: 10.3390/jcm10214961 PMID: 34768480
  52. Darb Emamie, A.; Rajabpour, M.; Ghanavati, R.; Asadolahi, P.; Farzi, S.; Sobouti, B.; Darbandi, A. The effects of probiotics, prebiotics and synbiotics on the reduction of IBD complications, a periodic review during 2009–2020. J. Appl. Microbiol., 2021, 130(6), 1823-1838. doi: 10.1111/jam.14907 PMID: 33098703
  53. Agraib, L.M.; Yamani, M.I.; Tayyem, R.; Abu-Sneineh, A.T.; Rayyan, Y.M. Probiotic supplementation induces remission and changes in the immunoglobulins and inflammatory response in active ulcerative colitis patients: A pilot, randomized, double-blind, placebo-controlled study. Clin. Nutr. ESPEN, 2022, 51, 83-91. doi: 10.1016/j.clnesp.2022.08.020 PMID: 36184252
  54. Kaur, L.; Gordon, M.; Baines, P.A.; Iheozor-Ejiofor, Z.; Sinopoulou, V.; Akobeng, A.K. Probiotics for induction of remission in ulcerative colitis. Cochrane Database Syst Rev, 2020, 3(3), CD005573.
  55. Naseer, M.; Poola, S.; Ali, S.; Samiullah, S.; Tahan, V. Prebiotics and probiotics in inflammatory bowel disease: Where are we now and where are we going? Curr. Clin. Pharmacol., 2020, 15(3), 216-233. doi: 10.2174/22123938MTA1pMTY42 PMID: 32164516
  56. Kamarli Altun, H.; Akal Yildiz, E.; Akin, M. Effects of synbiotic therapy in mild-to-moderately active ulcerative colitis: A randomized placebo-controlled study. Turk. J. Gastroenterol., 2019, 30(4), 313-320. doi: 10.5152/tjg.2019.18356 PMID: 30666969
  57. van der Waal, M.B.; Flach, J.; Browne, P.D.; Besseling-van der Vaart, I.; Claassen, E.; van de Burgwal, L.H.M. Probiotics for improving quality of life in ulcerative colitis: Exploring the patient perspective. PharmaNutrition, 2019, 7, 100139. doi: 10.1016/j.phanu.2018.100139
  58. Matsuoka, K.; Uemura, Y.; Kanai, T.; Kunisaki, R.; Suzuki, Y.; Yokoyama, K.; Yoshimura, N.; Hibi, T. Efficacy of Bifidobacterium breve fermented milk in maintaining remission of ulcerative colitis. Dig. Dis. Sci., 2018, 63(7), 1910-1919. doi: 10.1007/s10620-018-4946-2 PMID: 29450747
  59. Sun, Y.Y.; Li, M.; Li, Y.Y.; Li, L.X.; Zhai, W.Z.; Wang, P.; Yang, X.X.; Gu, X.; Song, L.J.; Li, Z.; Zuo, X.L.; Li, Y.Q. The effect of Clostridium butyricum on symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: A randomized, double-blind, placebo-controlled trial. Sci. Rep., 2018, 8(1), 2964. doi: 10.1038/s41598-018-21241-z PMID: 29445178
  60. Palumbo, V.D.; Romeo, M.; Gammazza, A.M.; Carini, F.; Damiani, P.; Damiano, G.; Buscemi, S.; Lo Monte, A.I.; Gerges-Geagea, A.; Jurjus, A.; Tomasello, G. The long-term effects of probiotics in the therapy of ulcerative colitis: A clinical study. Biomedical Papers, 2016, 160. doi: 10.5507/bp.2016.044
  61. Fedorak, R.N.; Feagan, B.G.; Hotte, N.; Leddin, D.; Dieleman, L.A.; Petrunia, D.M.; Enns, R.; Bitton, A.; Chiba, N.; Paré, P.; Rostom, A.; Marshall, J.; Depew, W.; Bernstein, C.N.; Panaccione, R.; Aumais, G.; Steinhart, A.H.; Cockeram, A.; Bailey, R.J.; Gionchetti, P.; Wong, C.; Madsen, K. The probiotic VSL#3 has anti-inflammatory effects and could reduce endoscopic recurrence after surgery for Crohn’s disease. Clin. Gastroenterol. Hepatol., 2015, 13(5), 928-935.e2. doi: 10.1016/j.cgh.2014.10.031 PMID: 25460016
  62. Shadnoush, M.; Hosseini, R.S.; Khalilnezhad, A.; Navai, L.; Goudarzi, H.; Vaezjalali, M. Effects of probiotics on gut microbiota in patients with inflammatory bowel disease: A double-blind, placebo-controlled clinical trial. Korean J. Gastroenterol., 2015, 65(4), 215-221. doi: 10.4166/kjg.2015.65.4.215 PMID: 25896155
  63. Petersen, A.M.; Mirsepasi, H.; Halkjær, S.I.; Mortensen, E.M.; Nordgaard-Lassen, I.; Krogfelt, K.A. Ciprofloxacin and probiotic Escherichia coli nissle add-on treatment in active ulcerative colitis: A double-blind randomized placebo controlled clinical trial. J. Crohns Colitis, 2014, 8 doi: 10.1016/j.crohns.2014.06.001
  64. Yoon, J.S.; Sohn, W.; Lee, O.Y.; Lee, S.P.; Lee, K.N.; Jun, D.W.; Lee, H.L.; Yoon, B.C.; Choi, H.S.; Chung, W.S.; Seo, J.G. Effect of multispecies probiotics on irritable bowel syndrome: A randomized, double-blind, placebo-controlled trial. J. Gastroenterol. Hepatol., 2014, 29(1), 52-59. doi: 10.1111/jgh.12322 PMID: 23829297
  65. Sniffen, J.C.; McFarland, L.V.; Evans, C.T.; Goldstein, E.J.C. Choosing an appropriate probiotic product for your patient: An evidence-based practical guide. PLoS One, 2018, 13(12), e0209205. doi: 10.1371/journal.pone.0209205 PMID: 30586435
  66. Mora, D.; Filardi, R.; Arioli, S.; Boeren, S.; Aalvink, S.; de Vos, W.M. Development of omics-based protocols for the microbiological characterization of multi-strain formulations marketed as probiotics: The case of VSL#3. Microb. Biotechnol., 2019, 12(6), 1371-1386. doi: 10.1111/1751-7915.13476 PMID: 31402586
  67. Kruis, W.; Schütz, E.; Fric, P.; Fixa, B.; Judmaier, G.; Stolte, M. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment. Pharmacol. Ther., 1997, 11(5), 853-858. doi: 10.1046/j.1365-2036.1997.00225.x PMID: 9354192
  68. Jia, K.; Tong, X.; Wang, R.; Song, X. The clinical effects of probiotics for inflammatory bowel disease: A meta-analysis. Medicine, 2018, 97(51), e13792.
  69. Gionchetti, P.; Rizzello, F.; Venturi, A.; Brigidi, P.; Matteuzzi, D.; Bazzocchi, G.; Poggioli, G.; Miglioli, M.; Campieri, M. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: A double-blind, placebo-controlled trial. Gastroenterology, 2000, 119(2), 305-309. doi: 10.1053/gast.2000.9370 PMID: 10930365
  70. Bibiloni, R.; Fedorak, R.N.; Tannock, G.W.; Madsen, K.L.; Gionchetti, P.; Campieri, M.; De Simone, C.; Sartor, R.B. VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am. J. Gastroenterol., 2005, 100(7), 1539-1546. doi: 10.1111/j.1572-0241.2005.41794.x PMID: 15984978
  71. Guslandi, M.; Mezzi, G.; Sorghi, M.; Testoni, P.A. Saccharomyces boulardii in maintenance treatment of Crohn’s disease. Dig. Dis. Sci., 2000, 45(7), 1462-1464. doi: 10.1023/A:1005588911207 PMID: 10961730
  72. Limketkai, B.N.; Akobeng, A.K.; Gordon, M.; Adepoju, A.A. Probiotics for induction of remission in Crohn's disease. Cochrane Database Syst. Rev., 2020, 7(7), CD006634.
  73. Chua, K.J.; Ling, H.; Hwang, I.Y.; Lee, H.L.; March, J.C.; Lee, Y.S.; Chang, M.W. An engineered probiotic produces a type III interferon IFNL1 and reduces inflammations in in vitro inflammatory bowel disease models. ACS Biomater. Sci. Eng., 2023, 9(9), 5123-5135. doi: 10.1021/acsbiomaterials.2c00202 PMID: 36399014
  74. Chua, K.J.; Kwok, W.C.; Aggarwal, N.; Sun, T.; Chang, M.W. Designer probiotics for the prevention and treatment of human diseases. Curr. Opin. Chem. Biol., 2017, 40, 8-16. doi: 10.1016/j.cbpa.2017.04.011 PMID: 28478369
  75. Falloon, K.; Cohen, B.; Ananthakrishnan, A.N.; Barnes, E.L.; Bhattacharya, A.; Colombel, J.F.; Cross, R.K.; Driscoll, M.S.; Fernandez, A.P.; Ha, C.; Herfarth, H.; Horst, S.; Hou, J.; Husni, M.E.; Kroshinsky, D.; Kuhn, K.A.; Lowder, C.Y.; Martin, G.; Parikh, D.; Sayed, C.J.; Schocket, L.; Siaton, B.C.; Vedak, P.; Weisman, M.H.; Rieder, F. A United States expert consensus to standardise definitions, follow-up, and treatment targets for extra-intestinal manifestations in inflammatory bowel disease. Aliment. Pharmacol. Ther., 2022, 55(9), 1179-1191. doi: 10.1111/apt.16853 PMID: 35277863
  76. Wan, Q.; Zhao, R.; Xia, L.; Wu, Y.; Zhou, Y.; Wang, Y.; Cui, Y.; Shen, X.; Wu, X.T. Inflammatory bowel disease and risk of gastric, small bowel and colorectal cancer: A meta-analysis of 26 observational studies. J. Cancer Res. Clin. Oncol., 2021, 147(4), 1077-1087. doi: 10.1007/s00432-020-03496-0 PMID: 33433655
  77. Hassan, D.S.; Hasary, H.J.; Hassan, Z.S. Role of probiotics in the prevention and treatment of GIT cancers: Updated review. AJMS, 2023, 4, 52-59. doi: 10.54133/ajms.v4i.103
  78. D’Amico, F.; Barone, M.; Tavella, T.; Rampelli, S.; Brigidi, P.; Turroni, S. Host microbiomes in tumor precision medicine: How far are we? Curr. Med. Chem., 2022, 29(18), 3202-3230. doi: 10.2174/0929867329666220105121754 PMID: 34986765
  79. Javanmard, A.; Ashtari, S.; Sabet, B.; Davoodi, S.H.; Rostami-Nejad, M.; Esmaeil Akbari, M.; Niaz, A.; Mortazavian, A.M. Probiotics and their role in gastrointestinal cancers prevention and treatment; An overview. Gastroenterol. Hepatol. Bed Bench, 2018, 11(4), 284-295. PMID: 30425806
  80. Nori, W.; Kassim, M.A.K.; Pantazi, A.C. Probiotics role in reducing GIT cancer-related therapy side effects. In: AJMS; , 2023; 5, pp. 114-115.
  81. Huang, V.W.; Chang, H.J.; Kroeker, K.I.; Goodman, K.J.; Hegadoren, K.M.; Dieleman, L.A.; Fedorak, R.N. Does the level of reproductive knowledge specific to inflammatory bowel disease predict childlessness among women with inflammatory bowel disease? Can. J. Gastroenterol. Hepatol., 2015, 29(2), 95-103. doi: 10.1155/2015/715354 PMID: 25803020
  82. Nori, W.; Shallal, F.; Zghair, M.A.G. Aspirin effect on mid luteal phase doppler indices in patients with recurrent pregnancy loss. Int. J. Pharm. Res., 2020, 12(3), 2929. doi: 10.31838/ijpr/2020.12.03.413
  83. Tavernier, N.; Fumery, M.; Peyrin-Biroulet, L.; Colombel, J.F.; Gower-Rousseau, C. Systematic review: Fertility in non-surgically treated inflammatory bowel disease. Aliment. Pharmacol. Ther., 2013, 38(8), 847-853. doi: 10.1111/apt.12478 PMID: 24004045
  84. Vincenti, A.; Loperfido, F.; De Giuseppe, R.; Manuelli, M.; Bosoni, D.; Righi, A.; Nappi, R.E.; Cena, H. Crohn’s disease and female infertility: Can nutrition play a supporting role? Nutrients, 2022, 14(12), 2423. doi: 10.3390/nu14122423 PMID: 35745153
  85. Cai, H.; Cao, X.; Qin, D.; Liu, Y.; Liu, Y.; Hua, J.; Peng, S. Gut microbiota supports male reproduction via nutrition, immunity, and signaling. Front. Microbiol., 2022, 13, 977574. doi: 10.3389/fmicb.2022.977574 PMID: 36060736
  86. Feng, T.; Wang, J. Oxidative stress tolerance and antioxidant capacity of lactic acid bacteria as probiotic: A systematic review. Gut Microbes, 2020, 12(1), 1801944. doi: 10.1080/19490976.2020.1801944 PMID: 32795116
  87. Magill, R.G.; MacDonald, S.M. Male infertility and the human microbiome. Front Reprod Health., 2023, 5, 1166201.
  88. Lewandowski, K.; Kaniewska, M.; Więcek, M.; Szwarc, P.; Panufnik, P.; Tulewicz-Marti, E.; Walicka, M.; Franek, E.; Rydzewska, G. Risk factors for osteoporosis among patients with inflammatory bowel disease—do we already know everything? Nutrients, 2023, 15(5), 1151. doi: 10.3390/nu15051151 PMID: 36904150
  89. Roomi, A.B.; Nori, W.; Al-Badry, S.H. The value of serum adiponectin in osteoporotic women: Does weight have an effect? J. Obes., 2021, 2021, 1-5. doi: 10.1155/2021/5325813 PMID: 34796028
  90. Seeman, E.; Martin, T.J. Antiresorptive and anabolic agents in the prevention and reversal of bone fragility. Nat. Rev. Rheumatol., 2019, 15(4), 225-236. doi: 10.1038/s41584-019-0172-3 PMID: 30755735
  91. Akram, N.N.; Jaafar, M.M.; Abdulqader, S.K.; Nori, W.; Kassim, M.A.K.; Pantazi, A.C. Clinical characteristics and therapeutic management of osteogenesis imperfecta in Iraqi children. AJMS, 2023, 5, S189-S194. doi: 10.54133/ajms.v5i1S.416
  92. Chen, Z.; Cai, Z.; Zhuang, P.; Li, F.; Cui, W.; Li, Z. Living probiotic biomaterials for osteoporosis therapy. Biomedical Technology, 2023, 1, 52-64. doi: 10.1016/j.bmt.2022.11.007
  93. Chen, Y.C.; Greenbaum, J.; Shen, H.; Deng, H.W. Association between gut microbiota and bone health: Potential mechanisms and prospective. J. Clin. Endocrinol. Metab., 2017, 102(10), 3635-3646. doi: 10.1210/jc.2017-00513 PMID: 28973392
  94. Lan, H.; Liu, W.H.; Zheng, H.; Feng, H.; Zhao, W.; Hung, W.L.; Li, H. Bifidobacterium lactis BL-99 protects mice with osteoporosis caused by colitis via gut inflammation and gut microbiota regulation. Food Funct., 2022, 13(3), 1482-1494. doi: 10.1039/D1FO02218K PMID: 35060590
  95. Harahap, I.A.; Suliburska, J. Can probiotics decrease the risk of postmenopausal osteoporosis in women? PharmaNutrition, 2023, 24, 100336. doi: 10.1016/j.phanu.2023.100336
  96. Sleutjes, J.A.M.; van der Woude, C.J.; Verploegh, P.J.P.; Aribas, E.; Kavousi, M.; Roeters van Lennep, J.E.; de Vries, A.C. Cardiovascular risk profiles in patients with inflammatory bowel disease differ from matched controls from the general population. Eur. J. Prev. Cardiol., 2023, 30(15), 1615-1622. doi: 10.1093/eurjpc/zwad124 PMID: 37075221
  97. Bunu, D.M.; Timofte, C.E.; Ciocoiu, M.; Floria, M.; Tarniceriu, C.C.; Barboi, O.B.; Tanase, D.M. Cardiovascular manifestations of inflammatory bowel disease: Pathogenesis, diagnosis, and preventive strategies. Gastroenterol Res Pract., 2019, 2019, 3012509.
  98. Dixon, A.; Robertson, K.; Yung, A.; Que, M.; Randall, H.; Wellalagodage, D.; Cox, T.; Robertson, D.; Chi, C.; Sun, J. Efficacy of probiotics in patients of cardiovascular disease risk: A systematic review and meta-analysis. Curr. Hypertens. Rep., 2020, 22(9), 74. doi: 10.1007/s11906-020-01080-y PMID: 32860083
  99. Biondi, R.B.; Salmazo, P.S.; Bazan, S.G.Z.; Hueb, J.C.; Paiva, S.A.R.; Sassaki, L.Y. Cardiovascular risk in individuals with inflammatory bowel disease. Clin. Exp. Gastroenterol., 2020, 13, 107-113. doi: 10.2147/CEG.S243478 PMID: 32425576
  100. Zhai, T.; Wang, P.; Hu, X.; Zheng, L. Probiotics bring new hope for atherosclerosis prevention and treatment. Oxid. Med. Cell Longev., 2022, 2022, 3900835. doi: 10.1155/2022/3900835
  101. Longoria, C.R.; Guers, J.J.; Campbell, S.C. The Interplay between cardiovascular disease, exercise, and the gut microbiome. Rev. Cardiovasc. Med., 2022, 23(11), 365. doi: 10.31083/j.rcm2311365
  102. Kelly, T.N.; Bazzano, L.A.; Ajami, N.J.; He, H.; Zhao, J.; Petrosino, J.F.; Correa, A.; He, J. Gut microbiome associates with lifetime cardiovascular disease risk profile among bogalusa heart study participants. Circ. Res., 2016, 119(8), 956-964. doi: 10.1161/CIRCRESAHA.116.309219 PMID: 27507222
  103. Han, Y.; Gong, Z.; Sun, G.; Xu, J.; Qi, C.; Sun, W.; Jiang, H.; Cao, P.; Ju, H. Dysbiosis of gut microbiota in patients with acute myocardial infarction. Front. Microbiol., 2021, 12, 680101. doi: 10.3389/fmicb.2021.680101 PMID: 34295318
  104. Qian, X.; Liu, A.; Liang, C.; He, L.; Xu, Z.; Tang, S. Analysis of gut microbiota in patients with acute myocardial infarction by 16S rRNA sequencing. Ann. Transl. Med., 2022, 10(24), 1340. doi: 10.21037/atm-22-5671 PMID: 36660636
  105. Zhong, X.; Zhao, Y.; Huang, L.; Liu, J.; Wang, K.; Gao, X.; Zhao, X.; Wang, X. Remodeling of the gut microbiome by Lactobacillus johnsonii alleviates the development of acute myocardial infarction. Front. Microbiol., 2023, 14, 1140498. doi: 10.3389/fmicb.2023.1140498 PMID: 36970663
  106. Gomes, T.T.; Mangini, S.; Marcondes-Braga, F.G.; Avila, M.S.; Campos, I.W.; Santos, F.B.; Seguro, L.F.; Bacal, F. Influence of probiotic supplementation in inflammatory profile of patients with heart failure - study PROBHF: A clinical trial, randomized, double-blind, placebo-controlled. J. Heart Lung Transplant., 2022, 41(4), S203. doi: 10.1016/j.healun.2022.01.1645
  107. Moludi, J.; Saiedi, S.; Ebrahimi, B.; Alizadeh, M.; Khajebishak, Y.; Ghadimi, S.S. Probiotics supplementation on cardiac remodeling following myocardial infarction: A single-center double-blind clinical study. J. Cardiovasc. Transl. Res., 2021, 14(2), 299-307. doi: 10.1007/s12265-020-10052-1 PMID: 32681453
  108. Moludi, J.; Alizadeh, M.; Mohammadzad, M.H.S.; Davari, M. The effect of probiotic supplementation on depressive symptoms and quality of life in patients after myocardial infarction: Results of a preliminary double-blind clinical trial. Psychosom. Med., 2019, 81(9), 770-777. doi: 10.1097/PSY.0000000000000749 PMID: 31592939
  109. Wu, Z.X.; Li, S.F.; Chen, H.; Song, J.X.; Gao, Y.F.; Zhang, F.; Cao, C.F. The changes of gut microbiota after acute myocardial infarction in rats. PLoS One, 2017, 12(7), e0180717. doi: 10.1371/journal.pone.0180717 PMID: 28686722
  110. Costanza, A.C.; Moscavitch, S.D.; Faria Neto, H.C.C.; Mesquita, E.T. Probiotic therapy with Saccharomyces boulardii for heart failure patients: A randomized, double-blind, placebo-controlled pilot trial. Int. J. Cardiol., 2015, 179, 348-350. doi: 10.1016/j.ijcard.2014.11.034 PMID: 25464484
  111. Yuan, X.; Chen, B.; Duan, Z.; Xia, Z.; Ding, Y.; Chen, T.; Liu, H.; Wang, B.; Yang, B.; Wang, X.; Liu, S.; Zhou, J.Y.; Liu, Y.; Wang, Q.; Shen, Z.; Xiao, J.; Shang, H.; Liu, W.; Shi, G.; Zhu, L.; Chen, Y. Depression and anxiety in patients with active ulcerative colitis: crosstalk of gut microbiota, metabolomics and proteomics. Gut Microbes, 2021, 13(1), 1987779. doi: 10.1080/19490976.2021.1987779 PMID: 34806521
  112. Sasso, J.M.; Ammar, R.M.; Tenchov, R.; Lemmel, S.; Kelber, O.; Grieswelle, M.; Zhou, Q.A. Gut microbiome-brain alliance: A landscape view into mental and gastrointestinal health and disorders. ACS Chem. Neurosci., 2023, 14(10), 1717-1763. doi: 10.1021/acschemneuro.3c00127 PMID: 37156006
  113. Sharma, A.; Sharma, V. The gut-brain connection: A case report on depression in ulcerative colitis and novel treatment approach. Cureus, 2023, 15(11), e48462. doi: 10.7759/cureus.48462 PMID: 38073991
  114. Darmadi, D.; Ariestine, D.A.; Surja, S.S. Role of probiotics in inflammatory bowel disease. Rawal Med. J., 2023, 48(2), p. 537.
  115. Bremmer, A. The efficacy and role of probiotics for maintenance of remission in crohn’s disease: A meta-analysis and survey. Open J. Gastroenterol., 2023, 13(5), 171-198. doi: 10.4236/ojgas.2023.135018
  116. Vakadaris, G.; Stefanis, C.; Giorgi, E.; Brouvalis, M.; Voidarou, C.C.; Kourkoutas, Y.; Tsigalou, C.; Bezirtzoglou, E. The role of probiotics in inducing and maintaining remission in Crohn’s disease and ulcerative colitis: A systematic review of the literature. Biomedicines, 2023, 11(2), 494. doi: 10.3390/biomedicines11020494 PMID: 36831029
  117. Zhang, X.F.; Guan, X.X.; Tang, Y.J.; Sun, J.F.; Wang, X.K.; Wang, W.D.; Fan, J.M. Clinical effects and gut microbiota changes of using probiotics, prebiotics or synbiotics in inflammatory bowel disease: A systematic review and meta-analysis. Eur. J. Nutr., 2021, 60(5), 2855-2875. doi: 10.1007/s00394-021-02503-5 PMID: 33555375
  118. Pabón-Carrasco, M.; Ramirez-Baena, L.; Vilar-Palomo, S.; Castro-Méndez, A.; Martos-García, R.; Rodríguez-Gallego, I. Probiotics as a coadjuvant factor in active or quiescent inflammatory bowel disease of adults-A meta-analytical study. Nutrients, 2020, 12(9), 2628. doi: 10.3390/nu12092628 PMID: 32872272
  119. Dore, M.P.; Bibbò, S.; Fresi, G.; Bassotti, G.; Pes, G.M. Side effects associated with probiotic use in adult patients with inflammatory bowel disease: A systematic review and meta-analysis of randomized controlled trials. Nutrients, 2019, 11(12), 2913. doi: 10.3390/nu11122913 PMID: 31810233
  120. Eindor-Abarbanel, A.; Healey, G.R.; Jacobson, K. Therapeutic advances in gut microbiome modulation in patients with inflammatory bowel disease from pediatrics to adulthood. Int. J. Mol. Sci., 2021, 22(22), 12506. doi: 10.3390/ijms222212506 PMID: 34830388
  121. Lomer, M.C.E.; Wilson, B.; Wall, C.L. British dietetic association consensus guidelines on the nutritional assessment and dietary management of patients with inflammatory bowel disease. J. Hum. Nutr. Diet., 2023, 36(1), 336-377. doi: 10.1111/jhn.13054 PMID: 35735908
  122. Szajewska, H.; Berni Canani, R.; Domellöf, M.; Guarino, A.; Hojsak, I.; Indrio, F.; Lo Vecchio, A.; Mihatsch, W.A.; Mosca, A.; Orel, R.; Salvatore, S.; Shamir, R.; van den Akker, C.H.P.; van Goudoever, J.B.; Vandenplas, Y.; Weizman, Z. Probiotics for the management of pediatric gastrointestinal disorders: Position paper of the ESPGHAN special interest group on gut microbiota and modifications. J. Pediatr. Gastroenterol. Nutr., 2023, 76(2), 232-247. doi: 10.1097/MPG.0000000000003633 PMID: 36219218
  123. Müller, L.; Lorentz, A. Probiotics in the treatment of inflammatory bowel diseases in adulthood: A systematic review. J. Gastrointestin. Liver Dis., 2022, 31(1), 74-84.
  124. Aghamohammad, S.; Sepehr, A.; Miri, S.T.; Najafi, S.; Pourshafie, M.R.; Rohani, M. The role of combining probiotics in preventing and controlling inflammation: A focus on the anti-inflammatory and immunomodulatory effects of probiotics in an in vitro model of IBD. Can. J. Gastroenterol. Hepatol., 2022, 2022, 1-9. doi: 10.1155/2022/2045572 PMID: 36397951

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© Bentham Science Publishers, 2024